Panobinostat, bortezomib, and dexamethasone

[youtube id=”mZFJaQoLcgA” width=”600″ height=”350″ autoplay=”no” api_params=”” class=””]
Jatin J. Shah, MD; Maria-Victoria Mateos, MD, PhD; and Andrew Spencer, MD, share their experiences using the triplet combination of panobinostat, bortezomib, and dexamethasone in relapsed/refractory multiple

[youtube id=”pjaMdghgenw” width=”600″ height=”350″ autoplay=”no” api_params=”” class=””]
At the 20th Congress of the European Hematology Association (EHA), Jesús F. San Miguel, MD, of the Clínica Universidad de Navarra, Navarra, Spain, discusses the results of a predefined subgroup analysis of the PANORAMA 1 trial, which evaluated the histone deacetylase inhibitor, panobinostat, plus bortezomib